Theravance Biopharma (NASDAQ:TBPH) Price Target Raised to $27.00

Theravance Biopharma (NASDAQ:TBPH) had its target price boosted by HC Wainwright from $20.00 to $27.00 in a research report released on Monday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock.

Other research analysts have also issued research reports about the company. BTIG Research restated a “buy” rating and set a $40.00 price objective on shares of Theravance Biopharma in a research report on Tuesday, February 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a report on Thursday, January 22nd. Oppenheimer assumed coverage on Theravance Biopharma in a research note on Wednesday, December 3rd. They issued an “outperform” rating and a $27.00 price objective on the stock. Finally, Wall Street Zen downgraded Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Theravance Biopharma presently has an average rating of “Moderate Buy” and a consensus target price of $22.60.

Theravance Biopharma Stock Performance

Shares of NASDAQ:TBPH opened at $13.66 on Monday. The firm has a market cap of $692.15 million, a price-to-earnings ratio of 23.96 and a beta of 0.17. The firm has a fifty day moving average price of $19.16 and a 200 day moving average price of $16.85. Theravance Biopharma has a fifty-two week low of $7.90 and a fifty-two week high of $21.03.

Hedge Funds Weigh In On Theravance Biopharma

Several large investors have recently modified their holdings of the stock. Arrowstreet Capital Limited Partnership bought a new stake in Theravance Biopharma in the third quarter worth $10,611,000. Assenagon Asset Management S.A. raised its stake in shares of Theravance Biopharma by 1,629.4% in the third quarter. Assenagon Asset Management S.A. now owns 414,715 shares of the biopharmaceutical company’s stock valued at $6,055,000 after acquiring an additional 390,735 shares during the period. Pacer Advisors Inc. purchased a new stake in shares of Theravance Biopharma in the fourth quarter valued at $6,342,000. Hillsdale Investment Management Inc. bought a new stake in shares of Theravance Biopharma in the 3rd quarter worth about $4,536,000. Finally, Janus Henderson Group PLC boosted its stake in shares of Theravance Biopharma by 214.8% during the 4th quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock worth $7,493,000 after purchasing an additional 273,288 shares during the period. Institutional investors own 99.10% of the company’s stock.

More Theravance Biopharma News

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Company retains a strong cash runway and announced deep cost cuts — Q4 cash ~$326.5M, roughly $400M expected at end‑Q1 2026; management expects ~60% cost reduction (~$70M) and $60–70M of annualized cash flow after restructuring. This improves near‑term survival and value for remaining assets. Read More.
• Positive Sentiment: HC Wainwright raised its price target to $27, signaling at least one analyst sees upside or acquisition/strategic outcomes that could unlock value. Read More.
• Neutral Sentiment: BTIG cut its price target from $40 to $21 but kept a “buy” rating — a mixed signal that trims optimism but still leaves upside from current levels per that firm. Read More.
• Neutral Sentiment: Board has accelerated a strategic review and is working with advisors (Lazard) to evaluate alternatives, including a possible sale — this creates near‑term uncertainty but could produce value for shareholders depending on outcome. Read More.
• Negative Sentiment: Core negative: The Phase 3 CYPRESS study of ampreloxetine missed its primary endpoint (OHSA composite), prompting the company to halt the program — this removes the company’s lead clinical value driver and was the catalyst for the sharp sell‑off. Read More.
• Negative Sentiment: B. Riley cut its price target sharply to $14 (from $28) and kept a neutral rating — another negative analyst move that reduces perceived near‑term upside. Read More.
• Negative Sentiment: Market positioning is bearish: unusually large put‑option activity was recorded (6,696 puts, ~983% above average), reflecting trader downside bets and adding selling pressure to the stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.